Hyperkalemia in patients with heart failure: Incidence, prevalence, and management
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hunt SA, Abraham WT, Chin MH, et al.: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391–e479.
Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543–551.
Rose BD, Post TW: Clinical physiology of acid-base and electrolyte disorders, edn 5. New York: McGraw-Hill, Medical Publishing Division; 2001.
Sweadner KJ, Goldin SM: Active transport of sodium and potassium ions: mechanism, function, and regulation. N Engl J Med 1980, 302:777–783.
Sterns RH, Cox M, Feig PU, Singer I: Internal potassium balance and the control of the plasma potassium concentration. Medicine 1981, 60:339–354.
Stanton BA: Regulation of Na+ and K+ transport by mineralocorticoids. Sem Nephrol 1987, 7:82–90.
Khuri RN, Strieder WN, Giebisch G: Effects of flow rate and potassium intake on distal tubular potassium transfer. Am J Physiol 1975, 228:1249–1261.
Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004, 351:585–592.
Bansal S, Lindenfeld, J, Schrier RW: Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2009, 2:370–376.
McMurray JJ, O’Meara E: Treatment of heart failure with spironolactone—trial and tribulations. N Engl J Med 2004, 351:526–528.
Rosa RM, Silva P, Young JB, et al.: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980, 302:431–434.
Sica DA, Hess M: Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure. Congest Heart Fail 2004, 10:259–264.
Desai AS, Swedberg K, McMurray JJ, et al.: Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 2007, 50:1959–1966.
Khanna A, White WB: The management of hyperkalemia in patients with cardiovascular disease. Am J Med 2009, 122:215–221.
Gonick HC, Kleeman CR, Rubini ME, Maxwell MH: Functional impairment in chronic renal disease. 3. Studies of potassium excretion. Am J Med Sci 1971, 261:281–290.
Einhorn LM, Zhan M, Hsu VD, et al.: The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009, 169:1156–1162.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325:293–302.
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327:685–691.
de Denus S, Tardif JC, White M, et al.: Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J 2006, 152:705–712.
Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759–766.
Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781.
McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.
Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.
Pitt B, Bakris G, Ruilope LM, et al.: Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008, 118:1643–1650.
Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.
Phillips CO, Kashani A, Ko DK, et al.: Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007, 167:1930–1936.
Desai A: Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit. Circulation 2008, 118:1609–1611.
Hillege HL, Nitsch D, Pfeffer MA, et al.: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671–678.
Bozkurt B, Agoston I, Knowlton AA: Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003, 41:211–214.
Shah KB, Rao K, Sawyer R, Gottlieb SS: The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005, 46:845–849.
Juurlink DN, Hansten PD: Drug safety in patients with heart failure. Arch Internal Med 2005, 165:118.
Massie BM, Carson PE, McMurray JJ, et al.: Irbesartan in patients with heart failure and preserved ejection fraction. The N Engl J Med 2008, 359:2456–2467.
Shlipak MG: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003, 138:917–924.
Campbell WB, Gomez-Sanchez CE, Adams BV, et al.: Attenuation of angiotensin II- and III-induced aldosterone release by prostaglandin synthesis inhibitors. J Clin Invest 1979, 64:1552–1557.
Akinbamowo AO, Salzberg DJ, Weir MR: Renal consequences of prostaglandin inhibition in heart failure. Heart Fail Clin 2008, 4:505–510.
Levy Yeyati N, Fellet A, Arranz C, et al.: Amiloridesensitive and amiloride-insensitive kaliuresis in advanced chronic kidney disease. J Nephrol 2008, 21:93–98.
Kleyman TR, Roberts C, Ling BN: A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995, 122:103–106.
Scoble JE, Varghese Z, Sweny P, Moorhead J: Renal physiology revisited: amiloride. Lancet 1986, 2:326–328.
Perazella MA: Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf 2000, 22:227–236.
Taylor DO, Barr ML, Radovancevic B, et al.: A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999, 18:336–345.
Stigant CE, Cohen J, Vivera M, Zaltzman JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000, 35:58–63.
Oster JR, Singer I, Fishman LM: Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995, 98:575–586.
Bay WH, Hartman JA: High potassium in low-sodium soups. N Engl J Med 1983, 308:1166–1167.
Ray K, Dorman S, Watson R: Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. J Hum Hypertens 1999, 13:717–720.